France

BC Partners has completed its acquisition from Servier of French generics giant Biogaran after the French government allowed the private-equity takeover on condition that BPI France take a minority stake. Meanwhile, former Biogaran CEO Erick Roche has returned to the role after a long stint at Teva.

While the regulatory environment for vaccines sours in the US, Valneva tells Scrip it is mulling an Asia hub and finalizing a strategy - that includes partnerships - for its marketed and pipeline products. Could it consider India or China as a new regional center?

A year after Valneva entered a tech transfer agreement for its chikungunya vaccine with Serum Institute, the deal has been called off. Regulatory approvals for the vaccine in Asia are yet to be obtained and the biologics license for Ixchiq remains suspended in the US. What happens hereon?

The French national assembly has adopted a version of the 2026 social security finance bill that includes price cuts and penalties for companies that adopt tactics to delay generic entry.

Deal Snapshot: Days after the disappointment of a mid-stage fail for its rare disease fidrisertib, Ipsen has hit the M&A trail to boost its oncology efforts and license an antibody-drug conjugate (ADC) from Simcere Zaiming.

The Paris-headquartered giant has put the spotlight on its extensive investments at home.

France is set to pilot a new fast-track process that could more than halve the timeline for authorizing certain clinical trial applications.

French biotech CellProthera is advancing to Phase III with its autologous CD34+ stem cell therapy that regenerates tissue after severe heart attacks.

Fines are a fact of life when it comes to manufacturers’ compliance with EU rules on persons responsible for regulatory compliance. But Italy’s stance adds pressure on individuals appointed to the role.

A French spending bill that would tax drug company turnover would create a “catastrophic competitiveness gap” between France and its European neighbors, warns Leem, the French pharmaceutical industry group.

Economic woes in France mean that tough and unpopular choices impacting the biopharmaceutical industry are inevitable, according to industry expert Alexandre Regniault.

The Paris-based group is paying €350m upfront to get hold of Marseille-headquartered ImCheck's acute myeloid leukemia candidate.